Document is current
Any future updates will be listed below
-
Authors
van Erning, Felice N.
Nieuwenhuijzen, Grard A. P.
van Laarhoven, Hanneke W. M.
Rosman, Camiel
Gisbertz, Suzanne S.
Heisterkamp, Joos
Lagarde, Sjoerd M.
Slingerland, Marije
van den Berg, Jan-Willem
Kouwenhoven, Ewout A.
Verhoeven, Rob H. A.
Vissers, Pauline A. J.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (UVA 2014-7000)
- License Information
-
More Information
Article History
Received: 29 March 2023
Accepted: 19 June 2023
First Online: 31 July 2023
Disclosure
: Authors FvE, GN, JWB, CR, SSG, SL, MS, JH, and PV have nothing to disclose. Author HvL: Consultant or advisory role for Amphera, AstraZeneca, Beigene, BMS, Daiichy-Sankyo, Dragonfly, Eli Lilly, MSD, Nordic Pharma, Servier. Received research funding and/or medication supply from Bayer, BMS, Celgene, Janssen, Incyte, Eli Lilly, MSD, Nordic Pharma, Philips, Roche, Servier. Received funds for speaker role from Astellas, Benecke, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Travel Congress Management BV. Author EK: Consultant or advisory role Intuitive Surgical. Author RV: Grant BMS, consultant role: Daiichi Sankyo. The data collection for POCOP was funded by the Dutch cancer society (project number: UVA 2014-7000). The funder had no role in the study design, data collection and analysis, preparation of the manuscript or decision to publish.
